KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to -$526.4 million.

  • Biomarin Pharmaceutical's Cash from Financing Activities rose 99.57% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.7 million, marking a year-over-year increase of 91.77%. This contributed to the annual value of -$526.4 million for FY2024, which is 2711.17% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Cash from Financing Activities stood at -$526.4 million for FY2024, which was down 2,711.17% from -$18.7 million recorded in FY2023.
  • Biomarin Pharmaceutical's Cash from Financing Activities' 5-year high stood at $181.1 million during FY2020, with a 5-year trough of -$526.4 million in FY2024.
  • For the 3-year period, Biomarin Pharmaceutical's Cash from Financing Activities averaged around -$187.9 million, with its median value being -$18.7 million (2023).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Cash from Financing Activities soared by 342.54% in 2020, and later slumped by 38,754.17% in 2022.
  • Biomarin Pharmaceutical's Cash from Financing Activities (Yearly) stood at $181.1 million in 2020, then slumped by 100.03% to -$48,000 in 2021, then slumped by 38,754.17% to -$18.6 million in 2022, then decreased by 0.41% to -$18.7 million in 2023, then tumbled by 2,711.17% to -$526.4 million in 2024.